288 related articles for article (PubMed ID: 22837011)
1. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice.
Lee IO; Kratz MT; Schirmer SH; Baumhäkel M; Böhm M
J Pharmacol Exp Ther; 2012 Nov; 343(2):253-7. PubMed ID: 22837011
[TBL] [Abstract][Full Text] [Related]
2. Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein e-knockout mice.
Baumhäkel M; Schlimmer N; Büyükafsar K; Arikan O; Böhm M
J Pharmacol Exp Ther; 2008 Jun; 325(3):818-23. PubMed ID: 18364472
[TBL] [Abstract][Full Text] [Related]
3. The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice : dabigatran etexilate and atherosclerosis.
Kadoglou NP; Moustardas P; Katsimpoulas M; Kapelouzou A; Kostomitsopoulos N; Schafer K; Kostakis A; Liapis CD
Cardiovasc Drugs Ther; 2012 Oct; 26(5):367-74. PubMed ID: 22940777
[TBL] [Abstract][Full Text] [Related]
4. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice.
Baumhäkel M; Custodis F; Schlimmer N; Laufs U; Böhm M
Atherosclerosis; 2010 Sep; 212(1):55-62. PubMed ID: 20347444
[TBL] [Abstract][Full Text] [Related]
5. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
Custodis F; Baumhäkel M; Schlimmer N; List F; Gensch C; Böhm M; Laufs U
Circulation; 2008 May; 117(18):2377-87. PubMed ID: 18443241
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice.
Preusch MR; Ieronimakis N; Wijelath ES; Cabbage S; Ricks J; Bea F; Reyes M; van Ryn J; Rosenfeld ME
Drug Des Devel Ther; 2015; 9():5203-11. PubMed ID: 26392754
[TBL] [Abstract][Full Text] [Related]
7. Improvement of endothelial function in a murine model of mild cholesterol-induced atherosclerosis by mineralocorticoid antagonism.
Kratz MT; Schirmer SH; Baumhäkel M; Böhm M
Atherosclerosis; 2016 Aug; 251():291-298. PubMed ID: 27439215
[TBL] [Abstract][Full Text] [Related]
8. Hydrogen sulfide regulates vascular endoplasmic reticulum stress in apolipoprotein E knockout mice.
Chen ZF; Zhao B; Tang XY; Li W; Zhu LL; Tang CS; DU JB; Jin HF
Chin Med J (Engl); 2011 Nov; 124(21):3460-7. PubMed ID: 22340159
[TBL] [Abstract][Full Text] [Related]
9. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo.
Hoyer FF; Steinmetz M; Zimmer S; Becker A; Lütjohann D; Buchalla R; Zimmer A; Nickenig G
J Mol Cell Cardiol; 2011 Dec; 51(6):1007-14. PubMed ID: 21884703
[TBL] [Abstract][Full Text] [Related]
10. The nitric oxide-donating pravastatin derivative, NCX 6550 [(1S-[1alpha(betaS*, deltaS*), 2alpha, 6alpha, 8beta-(R*), 8a alpha]]-1,2,6,7,8,8a-Hexahydro-beta, delta, 6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphtalene-heptanoic acid 4-(nitrooxy)butyl ester)], reduces splenocyte adhesion and reactive oxygen species generation in normal and atherosclerotic mice.
Dever G; Spickett CM; Kennedy S; Rush C; Tennant G; Monopoli A; Wainwright CL
J Pharmacol Exp Ther; 2007 Jan; 320(1):419-26. PubMed ID: 17005918
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
12. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knock out mice.
Tiyerili V; Mueller CF; Becher UM; Czech T; van Eickels M; Daiber A; Nickenig G; Wassmann S
J Mol Cell Cardiol; 2012 Mar; 52(3):630-7. PubMed ID: 22230040
[TBL] [Abstract][Full Text] [Related]
14. Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner.
Borissoff JI; Otten JJ; Heeneman S; Leenders P; van Oerle R; Soehnlein O; Loubele ST; Hamulyák K; Hackeng TM; Daemen MJ; Degen JL; Weiler H; Esmon CT; van Ryn J; Biessen EA; Spronk HM; ten Cate H
PLoS One; 2013; 8(2):e55784. PubMed ID: 23409043
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice.
Danzaki K; Matsui Y; Ikesue M; Ohta D; Ito K; Kanayama M; Kurotaki D; Morimoto J; Iwakura Y; Yagita H; Tsutsui H; Uede T
Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):273-80. PubMed ID: 22116098
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production.
Shimada K; Hirano E; Kimura T; Fujita M; Kishimoto C
Exp Biol Med (Maywood); 2012 Sep; 237(9):1039-44. PubMed ID: 22946091
[TBL] [Abstract][Full Text] [Related]
17. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice.
Bea F; Kreuzer J; Preusch M; Schaab S; Isermann B; Rosenfeld ME; Katus H; Blessing E
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2787-92. PubMed ID: 16990551
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice.
Wassmann S; Czech T; van Eickels M; Fleming I; Böhm M; Nickenig G
Circulation; 2004 Nov; 110(19):3062-7. PubMed ID: 15277329
[TBL] [Abstract][Full Text] [Related]
19. Vascular protease-activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long-term dabigatran administration - results from a diabetes animal model.
Scridon A; Mărginean A; Huțanu A; Chinezu L; Gheban D; Perian M; Vântu A; Gherțescu D; Fișcă PC; Șerban RC; Chevalier P; Dobreanu D
J Thromb Haemost; 2019 Mar; 17(3):538-550. PubMed ID: 30653813
[TBL] [Abstract][Full Text] [Related]
20. The long-term effect of angiotensin II type 1a receptor deficiency on hypercholesterolemia-induced atherosclerosis.
Eto H; Miyata M; Shirasawa T; Akasaki Y; Hamada N; Nagaki A; Orihara K; Biro S; Tei C
Hypertens Res; 2008 Aug; 31(8):1631-42. PubMed ID: 18971539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
